In the News

BioWorld 082123 Aulos Bioscience Thumbnail

Aulos Bioscience raises $20 million in series A to further alternative IL-2 approach

August 21, 2023 | PDF 49KB

CEO Aron Knickerbocker speaks with BioWorld about the company’s $20 million Series A extension funding, the science behind AU-007 and the latest on its Phase 1/2 clinical study in solid tumor cancers.

LSL Leading Aulos Bioscience’s “Triumvirate” Model Thumbnail
Life Science Leader

Leading Aulos Bioscience’s “Triumvirate” Model

June 1, 2023

During an interview with Life Science Leader, CEO Aron Knickerbocker discusses Aulos’ commitment to maximizing the ingenuity of a balanced team and continuing development of AU-007, the company’s lead candidate.

Dolgin-2022-Nature_Biotechnology Thumbnail
Nature Biotechnology

IL-2 upgrades show promise at ASCO

July 13, 2022

Nature Biotechnology looks at IL-2 therapeutics, including AU-007 and its unique ability to bind to IL-2, blocking activation of trimeric receptors on Tregs and endothelial cells while stimulating effector T cells and NK cells.